ArticleTobacco induced diseases2004
The pulmonary surfactant: impact of tobacco smoke and related compounds on surfactant and lung development.
Article in Tobacco induced diseases, 2004. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 33 citations in OpenAlex.
- Lipidomic signatures in lung adenocarcinoma and spontaneous pneumothorax tissues associated with heated tobacco use: a pilot study.BMC research notes · 2026Article
- A next-generation system for smoke inhalation integrated with a breathing lung-on-chip to model human lung responses to cigarette exposure.Scientific reports · 2025Article
- Particles in Exhaled Air (PExA): Clinical Uses and Future Implications.Diagnostics (Basel, Switzerland) · 2024Review
- Cigarette Smoke-Induced Respiratory Response: Insights into Cellular Processes and Biomarkers.Antioxidants (Basel, Switzerland) · 2023Review
- Mechanistic Understanding of Lung Inflammation: Recent Advances and Emerging Techniques.Journal of inflammation research · 2022Review
- Passive Vaping from Sub-Ohm Electronic Cigarette Devices.International journal of environmental research and public health · 2021Article
- Increased Monocyte-Derived CD11bFrontiers in immunology · 2021Article
- Cigarillos Compromise the Mucosal Barrier and Protein Expression in Airway Epithelia.American journal of respiratory cell and molecular biology · 2020Article
- Alveolar lipids in pulmonary disease. A review.Lipids in health and disease · 2020Review
- Metabolomics and transcriptomics pathway approach reveals outcome-specific perturbations in COPD.Scientific reports · 2018Article
- Gestational Exposure to Sidestream (Secondhand) Cigarette Smoke Promotes Transgenerational Epigenetic Transmission of Exacerbated Allergic Asthma and Bronchopulmonary Dysplasia.Journal of immunology (Baltimore, Md. : 1950) · 2017Article
- Electronic cigarettes: age-specific generation-resolved pulmonary doses.Environmental science and pollution research international · 2017Article
- Cellular reactions to long-term volatile organic compound (VOC) exposures.Scientific reports · 2016Article
- Pharmacokinetic studies for proving bioequivalence of orally inhaled drug products-critical issues and concepts.Frontiers in pharmacology · 2015Article
- Eosinophil-associated lung diseases. A cry for surfactant proteins A and D help?American journal of respiratory cell and molecular biology · 2014Review
- Surfactant phospholipid metabolism.Biochimica et biophysica acta · 2013Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cigarette smoking, one of the most pervasive habits in society, presents many well established health risks. While lung cancer is probably the most common and well documented disease associated with tobacco exposure, it is becoming clear from recent research that many other diseases are causally related to smoking. Whether from direct smoking or inhaling environmental tobacco smoke (ETS), termed secondhand smoke, the cells of the respiratory tissues and the lining pulmonary surfactant are the first body tissues to be directly exposed to the many thousands of toxic chemicals in tobacco. Considering the vast surface area of the lung and the extreme attenuation of the blood-air barrier, it is not surprising that this organ is the primary route for exposure, not just to smoke but to most environmental contaminants. Recent research has shown that the pulmonary surfactant, a complex mixture of phospholipids and proteins, is the first site of defense against particulates or gas components of smoke. However, it is not clear what effect smoke has on the surfactant. Most studies have demonstrated that smoking reduces bronchoalveolar lavage phospholipid levels. Some components of smoke also appear to have a direct detergent-like effect on the surfactant while others appear to alter cycling or secretion. Ultimately these effects are reflected in changes in the dynamics of the surfactant system and, clinically in changes in lung mechanics. Similarly, exposure of the developing fetal lung through maternal smoking results in postnatal alterations in lung mechanics and higher incidents of wheezing and coughing. Direct exposure of developing lung to nicotine induces changes suggestive of fetal stress. Furthermore, identification of nicotinic receptors in fetal lung airways and corresponding increases in airway connective tissue support a possible involvement of nicotine in postnatal asthma development. Finally, at the level of the alveoli of the lung, colocalization of nicotinic receptors and surfactant-specific protein in alveolar cells is suggestive of a role in surfactant metabolism. Further research is needed to determine the mechanistic effects of smoke and its components on surfactant function and, importantly, the effects of smoke components on the developing pulmonary system.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.